Duffy Sean P. sold $260K of OMDA

Duffy Sean P. (Chief Executive Officer) sold 14,960 shares of Omada Health, Inc. (OMDA) at $17.36 ($0.26M total) on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duffy Sean P.
Published Jun 18, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The disclosure adds transparency on insider transactions but does not include new guidance, financial results, or company-specific catalysts.

02

Market read

Traders may treat this as low-signal sentiment data rather than a fundamental catalyst.

03

What to watch

The article provides no context on total compensation, tax obligations, or whether other insiders are selling/buying around the same period.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-18, transaction dated 2026-06-16.

Background

The article is an SEC Form 4 disclosure of an insider sale by Omada Health CEO Sean Duffy.

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

Omada Health CEO Sean Duffy sold 14,960 shares in an open-market transaction at $17.3604 on 2026-06-16, per Form 4.

Expected impact

Likely minimal immediate price impact; any effect is more about sentiment than new company information.

Evidence & confidence

The filing is an SEC Form 4 insider transaction and explicitly notes a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider activity without operational or regulatory updates.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with valuation or liquidity needs, so traders may still watch for follow-on selling patterns.

Key entities

  • Omada Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Sean P. Duffy

    CEO and director who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.